Success Metrics

Active Trials
0(0%)

Phase Distribution

Ph phase_1
3
100%

Phase Distribution

3

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
3(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Other(3)

Detailed Status

unknown3

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
N/A
Most Advanced
Phase 1

Trials by Phase

Phase 13 (100.0%)

Trials by Status

unknown3100%

Recent Activity

0 active trials
Showing 3 of 3
unknownphase_1

NGS-MRD Assessment of Combination Immunotherapies Targeting T-ALL

NCT05277753
unknownphase_1

NGS-MRD Assessment of Combination Immunotherapies Targeting B-ALL

NCT05262673
unknownphase_1

Immunotherapy Based on Antigen-specific Immune Effector Cells Targeting Neurofibromatosis or Schwannomatosis

NCT04085159

Clinical Trials (3)

Showing 3 of 3 trials
NCT05277753Phase 1

NGS-MRD Assessment of Combination Immunotherapies Targeting T-ALL

Unknown
NCT05262673Phase 1

NGS-MRD Assessment of Combination Immunotherapies Targeting B-ALL

Unknown
NCT04085159Phase 1

Immunotherapy Based on Antigen-specific Immune Effector Cells Targeting Neurofibromatosis or Schwannomatosis

Unknown

All 3 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
3